CAJ | 학술논문

胰腺癌是一种恶性程度高、致死性强的疾病,5年生存率小于5％.虽然外科手术和药物的治疗有了较大的进步,但其预后不佳,这与药物的耐药性有密切关系.随着胰腺癌分子生物学研究的进展,目前可以根据患者的肿瘤组织活检特点进行胰腺癌靶向的个体化治疗.基于此,一些靶向于肿瘤细胞和肿瘤微环境的信号通路的新药正在进行前期临床试验.本文就胰腺癌的靶向治疗作简要综述.
이선암시일충악성정도고、치사성강적질병,5년생존솔소우5％.수연외과수술화약물적치료유료교대적진보,단기예후불가,저여약물적내약성유밀절관계.수착이선암분자생물학연구적진전,목전가이근거환자적종류조직활검특점진행이선암파향적개체화치료.기우차,일사파향우종류세포화종류미배경적신호통로적신약정재진행전기림상시험.본문취이선암적파향치료작간요종술.
Pancreatic ductal adenocarcinoma is a devastating and malignant disease,with a five year survival rate of less than 5％.Despite our improvement of surgical techniques and adjuvant medical therapy,most patients with pancreatic cancer have a dismal prognosis.The poor outcome of this tumor is associated with a high degree of drug resistance.Recently,the emerging knowledge of the molecular basis of pancreatic cancer may provide new avenues to get better prognostication for individual patients based on the molecular profile of obtained tissue by a biopsy or from resected specimens.So some novel drugs targeting signal pathway both within cancer cell and cancer microenvironment are undergoing preclinical.This article reviews the different targeted approaches in pancreatic cancer.